Another therapeutic agent targeting both IL-4 and IL-13, pitrakinra, a dual IL-4/IL-13 antagonist, reduced asthma exacerbations only in a subgroup of patients with specific gene polymorphisms of IL-4 receptor [203]. This evidence concerns the gene IL13 and asthma.